Product Details
Synonym
Nucleocapsid protein, NP, Protein N
Source
SARS-CoV-2 Nucleocapsid protein, His Tag (NUN-C5221) is expressed from human 293 cells (HEK293).
Request for sequenceMolecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 47.3 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Supplied as 0.2 μm filtered solution in 10 mM PB, 150 mM NaCl, pH7.4.
Contact us for customized product form or formulation.
Shipping
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Storage
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- The product MUST be stored at -70°C or lower upon receipt;
- -70°C for 3 months under sterile conditions.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

SARS-CoV-2 Nucleocapsid protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA

Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (Cat. No. NUN-CH15) with a linear range of 0.1-3 ng/mL (QC tested).
Protocol
Immobilized Anti-SARS-CoV-2 Nucleocapsid Antibody, Chimeric mAb, Human IgG1 (Cat. No. NUN-CH15) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) with a linear range of 0.1-3 ng/mL (QC tested).
Protocol
Immobilized SARS-CoV-2 Nucleocapsid protein, His Tag (Cat. No. NUN-C5221) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 NP Antibody, Rabbit MAb (CLN27) with a linear range of 0.05-2 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Nucleocapsid proteins
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 1 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















